166 related articles for article (PubMed ID: 38030302)
1. Delayed vaccine-induced CD8
van der Sluis TC; van Haften FJ; van Duikeren S; Pardieck IN; de Graaf JF; Vleeshouwers W; van der Maaden K; Melief CJM; van der Burg SH; Arens R
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030302
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination.
Tseng CW; Hung CF; Alvarez RD; Trimble C; Huh WK; Kim D; Chuang CM; Lin CT; Tsai YC; He L; Monie A; Wu TC
Clin Cancer Res; 2008 May; 14(10):3185-92. PubMed ID: 18483387
[TBL] [Abstract][Full Text] [Related]
3. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
4. Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death.
van der Sluis TC; van Duikeren S; Huppelschoten S; Jordanova ES; Beyranvand Nejad E; Sloots A; Boon L; Smit VT; Welters MJ; Ossendorp F; van de Water B; Arens R; van der Burg SH; Melief CJ
Clin Cancer Res; 2015 Feb; 21(4):781-94. PubMed ID: 25501579
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.
Lee SY; Kang TH; Knoff J; Huang Z; Soong RS; Alvarez RD; Hung CF; Wu TC
Cancer Immunol Immunother; 2013 Jul; 62(7):1175-85. PubMed ID: 23615841
[TBL] [Abstract][Full Text] [Related]
6. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy.
Bae SH; Park YJ; Park JB; Choi YS; Kim MS; Sin JI
Clin Cancer Res; 2007 Jan; 13(1):341-9. PubMed ID: 17200373
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 Vaccine against HPV Genome-Positive C3 Cancers in Mice.
Boilesen DR; Neckermann P; Willert T; Müller MD; Schrödel S; Pertl C; Thirion C; Asbach B; Wagner R; Holst PJ
Cancer Immunol Res; 2023 Feb; 11(2):261-275. PubMed ID: 36534088
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
[TBL] [Abstract][Full Text] [Related]
10. Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer.
Peng S; Wang JW; Karanam B; Wang C; Huh WK; Alvarez RD; Pai SI; Hung CF; Wu TC; Roden RB
PLoS One; 2015; 10(1):e116389. PubMed ID: 25560237
[TBL] [Abstract][Full Text] [Related]
11. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
[TBL] [Abstract][Full Text] [Related]
12. Live-attenuated lymphocytic choriomeningitis virus-based vaccines for active immunotherapy of HPV16-positive cancer.
Schmidt S; Bonilla WV; Reiter A; Stemeseder F; Kleissner T; Oeler D; Berka U; El-Gazzar A; Kiefmann B; Schulha SC; Raguz J; Habbeddine M; Scheinost M; Qing X; Lauterbach H; Matushansky I; Pinschewer DD; Orlinger KK
Oncoimmunology; 2020 Sep; 9(1):1809960. PubMed ID: 33457095
[TBL] [Abstract][Full Text] [Related]
13. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model.
Peng S; Tan M; Li YD; Cheng MA; Farmer E; Ferrall L; Gaillard S; Roden RBS; Hung CF; Wu TC
Cancer Immunol Immunother; 2021 Apr; 70(4):1049-1062. PubMed ID: 33108473
[TBL] [Abstract][Full Text] [Related]
14. Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents.
Zeng Q; Peng S; Monie A; Yang M; Pang X; Hung CF; Wu TC
Hum Gene Ther; 2011 Jul; 22(7):809-19. PubMed ID: 21128743
[TBL] [Abstract][Full Text] [Related]
15. Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16
Salomon N; Selmi A; Grunwitz C; Kong A; Stanganello E; Neumaier J; Petschenka J; Diken M; Kreiter S; Türeci Ö; Sahin U; Vascotto F
Cancer Immunol Immunother; 2022 Aug; 71(8):1975-1988. PubMed ID: 34971406
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment.
Song L; Yang MC; Knoff J; Wu TC; Hung CF
PLoS One; 2014; 9(12):e115711. PubMed ID: 25531529
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
18. T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity.
Lee SE; Shin AR; Sohn HJ; Cho HI; Kim TG
Cancer Res Treat; 2020 Jul; 52(3):747-763. PubMed ID: 32065848
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte-derived dendritic cells.
Lee JM; Shin KS; Koh CH; Song B; Jeon I; Park MH; Kim BS; Chung Y; Kang CY
Cancer Lett; 2021 Nov; 520():38-47. PubMed ID: 34224797
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
